{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-22-000003","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2022-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.142875+00:00","generated_at":"2026-06-27T13:18:30.856617+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Gilead Q4 GAAP EPS $0.30, revenue $7.2B (-2% YoY); 2022 guidance $23.8-24.3B","bullets":["GAAP diluted EPS $0.30 vs $1.23 YoY; non-GAAP $0.69 vs $2.19 (includes $1.25B legal charge)","Q4 product sales $7.2B (-2% YoY); ex-Veklury up 8% to $5.8B","Biktarvy sales up 22% YoY to $4.5B; Cell Therapy up 47% to $239M","2022 guidance: product sales $23.8-24.3B; GAAP EPS $4.70-5.20; non-GAAP EPS $6.20-6.70","Cash flow: $3.2B operating; debt repayment $1B; dividends $894M; cash $7.8B at Dec 31"],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-22-000003","json":"https://secwatch.observer/filing/0000882095-22-000003.json","markdown":"https://secwatch.observer/filing/0000882095-22-000003.md","text":"https://secwatch.observer/filing/0000882095-22-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000003/0000882095-22-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000003/gild-20220201.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T13:18:30.856617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}